Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
About this trial
This is an interventional treatment trial for Multiple Myeloma and Plasma Cell Neoplasm focused on measuring refractory multiple myeloma
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of multiple myeloma (MM) Relapsed or refractory disease Monoclonal immunoglobulin spike by serum electrophoresis of ≥ 1 gm/dL AND/OR urine monoclonal immunoglobulin spike of ≥ 200 mg/24 hours Has received ≥ 2 prior treatment regimens for MM None of the following are allowed: Non-secretory MM Plasma cell leukemia Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome PATIENT CHARACTERISTICS: Age Over 18 Performance status ECOG 0-2 Life expectancy More than 3 months Hematopoietic Platelet count ≥ 50,000/mm^3 (30,000/mm^3 if the bone marrow is extensively infiltrated) Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 1,000/mm^3 Hepatic AST and ALT < 3.0 times upper limit of normal (ULN) Bilirubin < 2.0 times ULN Renal Not specified Cardiovascular No cardiac disease, including any of the following conditions: History of recurrent supraventricular arrhythmia History of sustained ventricular tachycardia History of second or third degree AV block History of left bundle branch block Cardiomyopathy with LVEF < 40% Uncontrolled ischemic heart disease No myocardial infarction within the past 6 months No prolonged QT interval > 500 ms Other Not pregnant or nursing Negative pregnancy test No HIV positivity No neuropathy > grade 3 Potassium ≥ 4 mEq/L Magnesium ≥ 1.8 mg/dL PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Other More than 30 days since prior investigational drugs
Sites / Locations
- OHSU Knight Cancer Institute
Arms of the Study
Arm 1
Experimental
Arsenic Trioxide
Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid